{"id":1843,"date":"2023-04-18T16:36:00","date_gmt":"2023-04-18T14:36:00","guid":{"rendered":"https:\/\/niho.sk\/?p=1843"},"modified":"2024-08-01T14:14:23","modified_gmt":"2024-08-01T12:14:23","slug":"26a-liecivo-atezolizumab-tecentriq-na-liecbu-nemalobunkoveho-karcinomu-pluc-v-adjuvantnom-rezime-po-kompletnej-resekcii-a-po-chemoterapii-na-baze-platiny","status":"publish","type":"post","link":"https:\/\/niho.sk\/en\/26a-liecivo-atezolizumab-tecentriq-na-liecbu-nemalobunkoveho-karcinomu-pluc-v-adjuvantnom-rezime-po-kompletnej-resekcii-a-po-chemoterapii-na-baze-platiny\/","title":{"rendered":"26A: Lie\u010divo atezolizumab (Tecentriq) na lie\u010dbu nemalobunkov\u00e9ho karcin\u00f3mu p\u013e\u00fac v adjuvantnom re\u017eime po kompletnej resekcii a po chemoterapii na b\u00e1ze platiny"},"content":{"rendered":"
    \n
  1. Ak\u00e1 je z\u00e1\u0165a\u017e ochorenia pre pacienta? Ako z\u00e1sadn\u00e9 je ochorenie?<\/strong><\/li>\n<\/ol>\n\n\n\n

    Zhubn\u00fd n\u00e1dor p\u013e\u00fac je vo v\u00e4\u010d\u0161ine kraj\u00edn sveta naj\u010dastej\u0161ie diagnostikovanou malignitou u mu\u017eov a u \u017eien je celosvetovo na \u0161tvrtom mieste. Pr\u00ed\u010dinou v\u00e4\u010d\u0161iny pr\u00edpadov ochorenia je faj\u010denie. Zhubn\u00e9 n\u00e1dory p\u013e\u00fac boli v roku 2019 naj\u010dastej\u0161ou onkologickou pr\u00ed\u010dinou \u00famrtia mu\u017eov a druhou naj\u010dastej\u0161ou onkologickou pr\u00ed\u010dinou \u00famrtia \u017eien na Slovensku. Lie\u010dbou prvej vo\u013eby NSCLC je kurat\u00edvna resekcia s cie\u013eom kompletn\u00e9ho odstr\u00e1nenia n\u00e1doru. Tak\u00e1to oper\u00e1cia je v\u0161ak z d\u00f4vodu komorbid\u00edt a neskor\u00e9ho z\u00e1chytu ochorenia mo\u017en\u00e1 iba u okolo 15% pacientov.<\/p>\n\n\n\n

      \n
    1. O ak\u00fd liek ide?<\/strong><\/li>\n<\/ol>\n\n\n\n

      Tecentriq je liek proti rakovine, ktor\u00fd obsahuje lie\u010divo atezolizumab. Atezolizumab patr\u00ed do skupiny liekov naz\u00fdvanej monoklon\u00e1lne protil\u00e1tky. Monoklon\u00e1lna protil\u00e1tka je typ bielkoviny vytvorenej tak, aby rozpoznala a naviazala sa na \u0161pecifick\u00fd cie\u013e v tele. T\u00e1to protil\u00e1tka m\u00f4\u017ee pom\u00f4c\u0165 v\u00e1\u0161mu imunitn\u00e9mu syst\u00e9mu bojova\u0165 proti rakovine.<\/p>\n\n\n\n

      Tento liek bol prv\u00fdkr\u00e1t v Eur\u00f3pskej \u00fanii registrovan\u00fd 20.9.2017. N\u00e1sledne, 22.4.2022 bola registr\u00e1cia roz\u0161\u00edren\u00e1 aj o indik\u00e1ciu \u201cadjuvantn\u00e1 lie\u010dba po kompletnej resekcii v\u010dasn\u00e9ho \u0161t\u00e1dia po predch\u00e1dzaj\u00facej chemoterapii na b\u00e1ze platiny\u201d.<\/p>\n\n\n\n

        \n
      1. Ako sa na atezolizumab pozeraj\u00fa odborn\u00edci?\u00a0<\/strong><\/li>\n<\/ol>\n\n\n\n

        Klinick\u00fd odborn\u00edk by priv\u00edtal kategoriz\u00e1ciu Tecentriqu v indik\u00e1cii adjuvantnej lie\u010dby NSCLC, ke\u010f\u017ee v s\u00fa\u010dasnosti nie je v danej l\u00ednii dostupn\u00e1 \u017eiadna akt\u00edvna lie\u010dba. Na z\u00e1klade klinick\u00fdch v\u00fdsledkov predpoklad\u00e1 pr\u00ednos vo vy\u0161\u0161om po\u010dte pacientov v remisii, a teda men\u0161\u00ed po\u010det pacientov v zlo\u017eitej\u0161\u00edch metastatick\u00fdch \u0161t\u00e1di\u00e1ch.<\/p>\n\n\n\n

          \n
        1. \u010co hodnotilo NIHO a ak\u00fd je v\u00fdsledok?<\/strong><\/li>\n<\/ol>\n\n\n\n

          Dr\u017eite\u013e registr\u00e1cie (Roche Registration GmbH (DEU)) podal \u017eiados\u0165 o zaradenie lieku Tecentriq (lie\u010divo atezolizumab) do \u00fahrad z verejn\u00e9ho zdravotn\u00e9ho poistenia pri pou\u017eit\u00ed na lie\u010dbu nemalobunkov\u00e9ho karcin\u00f3mu p\u013e\u00fac v adjuvantnom re\u017eime po kompletnej resekcii a po chemoterapii na b\u00e1ze platiny.<\/p>\n\n\n\n

          NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie lieku Tecentriq v predmetnej indik\u00e1cii. Navrhovan\u00e1 \u00fahrada 3 890,77 \u20ac za balenie je n\u00e1kladovo efekt\u00edvna v zmysle \u00a77 z\u00e1kona 363\/2011 Z.z..<\/p>","protected":false},"excerpt":{"rendered":"

          NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie lieku Tecentriq v predmetnej indik\u00e1cii…<\/p>","protected":false},"author":3,"featured_media":1844,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[89,88],"class_list":["post-1843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sumar-hodnotenia","tag-atezolizumab","tag-tecentriq"],"_links":{"self":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts\/1843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/comments?post=1843"}],"version-history":[{"count":0,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts\/1843\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/media\/1844"}],"wp:attachment":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/media?parent=1843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/categories?post=1843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/tags?post=1843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}